| 0.087 0.006 (7.41%) | 12-01 15:56 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.11 | 1-year : | 0.13 |
| Resists | First : | 0.09 | Second : | 0.11 |
| Pivot price | 0.07  |
|||
| Supports | First : | 0.07 | Second : | 0.06 |
| MAs | MA(5) : | 0.07 |
MA(20) : | 0.07  |
| MA(100) : | 0.12 |
MA(250) : | 0.36 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 62.9 |
D(3) : | 50 |
| RSI | RSI(14): 54.9 |
|||
| 52-week | High : | 1.74 | Low : | 0.05 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ARDS ] has closed below upper band by 15.0%. Bollinger Bands are 57.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 53 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.09 - 0.09 | 0.09 - 0.09 |
| Low: | 0.07 - 0.07 | 0.07 - 0.07 |
| Close: | 0.08 - 0.08 | 0.08 - 0.08 |
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Fri, 03 Nov 2023
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update - Yahoo Finance
Wed, 02 Aug 2023
Aridis Pharmaceuticals Announces $2 Million Offering - Yahoo Finance
Tue, 18 Jul 2023
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday’s Mid-Da - Benzinga
Tue, 18 Jul 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace
Tue, 18 Jul 2023
Why Are Aridis Pharmaceuticals Shares Moving Higher Today? - Yahoo Finance
Thu, 13 Jul 2023
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 29.2 (%) |
| Held by Institutions | 12.1 (%) |
| Shares Short | 2,000 (K) |
| Shares Short P.Month | 440 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.26 |
| Profit Margin | -5.2 % |
| Operating Margin | -208.4 % |
| Return on Assets (ttm) | -4.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 4.5 % |
| Gross Profit (p.s.) | -0.51 |
| Sales Per Share | 0.5 |
| EBITDA (p.s.) | -0.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.55 |
| PEG Ratio | 0 |
| Price to Book value | -0.34 |
| Price to Sales | 0.17 |
| Price to Cash Flow | -0.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|